Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D F Nixon

Showing results (11-20 of 59) with videos related to

Pageof 6
Sort By:
International Immunology|January 1, 1990
Structural homologies between two HLA B27-restricted peptides suggest residues important for interaction with HLA B27S Huet, D F Nixon, J B Rothbard, et al.
Nature|December 1, 1988
HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptidesD F Nixon, A R Townsend, J G Elvin, et al.
Vaccine|November 19, 1997
CTL induction using synthetic peptides delivered in emulsions--critical role of the formulation procedureM Singh, C Hioe, H Qiu, et al.
Immunology Letters|April 15, 1999
Comparison of restimulation methods to elicit SIV specific cytotoxic T-lymphocytes (CTL) in vitro: Staphylococcal enterotoxin B (SEB) provides a novel method for the quantification of SIV specific CTL precursorsW M Kakimoto, A Gettie, S Smith, et al.
The Journal of Infectious Diseases|April 14, 2000
The relationship between T cell proliferative responses and plasma viremia during treatment of human immunodeficiency virus type 1 infection with combination antiretroviral therapyJ M Binley, D S Schiller, G M Ortiz, et al.
HIV Medicine|October 12, 2013
HIV-1 drug resistance prevalence, drug susceptibility and variant characterization in the Jacobi Medical Center paediatric cohort, Bronx, NY, USAM de Mulder, V A York, A A Wiznia, et al.
The Journal of Infectious Diseases|April 6, 2000
Strong human immunodeficiency virus (HIV)-specific CD4+ T cell responses in a cohort of chronically infected patients are associated with interruptions in anti-HIV chemotherapyP A Haslett, D F Nixon, Z Shen, et al.
AIDS Research and Human Retroviruses|March 15, 2000
Evaluation of a lipopeptide immunogen as a therapeutic in HIV type 1-seropositive individualsA Seth, Y Yasutomi, H Jacoby, et al.
Clinical and Vaccine Immunology : CVI|April 6, 2007
Rational peptide selection to detect human immunodeficiency virus type 1-specific T-cell responses under resource-limited conditionsC B Willberg, S K Pillai, E R Sharp, et al.
Scandinavian Journal of Immunology|January 16, 2004
Limited magnitude and breadth in the HLA-A2-restricted CD8 T-Cell response to Nef in children with vertically acquired HIV-1 infectionR Chandwani, K A Jordan, B L Shacklett, et al.
Pageof 6

Showing results (11-20 of 59) with videos related to

Sort By:
Pageof 6
International Immunology|January 1, 1990
Structural homologies between two HLA B27-restricted peptides suggest residues important for interaction with HLA B27S Huet, D F Nixon, J B Rothbard, et al.
Nature|December 1, 1988
HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptidesD F Nixon, A R Townsend, J G Elvin, et al.
Vaccine|November 19, 1997
CTL induction using synthetic peptides delivered in emulsions--critical role of the formulation procedureM Singh, C Hioe, H Qiu, et al.
Immunology Letters|April 15, 1999
Comparison of restimulation methods to elicit SIV specific cytotoxic T-lymphocytes (CTL) in vitro: Staphylococcal enterotoxin B (SEB) provides a novel method for the quantification of SIV specific CTL precursorsW M Kakimoto, A Gettie, S Smith, et al.
The Journal of Infectious Diseases|April 14, 2000
The relationship between T cell proliferative responses and plasma viremia during treatment of human immunodeficiency virus type 1 infection with combination antiretroviral therapyJ M Binley, D S Schiller, G M Ortiz, et al.
HIV Medicine|October 12, 2013
HIV-1 drug resistance prevalence, drug susceptibility and variant characterization in the Jacobi Medical Center paediatric cohort, Bronx, NY, USAM de Mulder, V A York, A A Wiznia, et al.
The Journal of Infectious Diseases|April 6, 2000
Strong human immunodeficiency virus (HIV)-specific CD4+ T cell responses in a cohort of chronically infected patients are associated with interruptions in anti-HIV chemotherapyP A Haslett, D F Nixon, Z Shen, et al.
AIDS Research and Human Retroviruses|March 15, 2000
Evaluation of a lipopeptide immunogen as a therapeutic in HIV type 1-seropositive individualsA Seth, Y Yasutomi, H Jacoby, et al.
Clinical and Vaccine Immunology : CVI|April 6, 2007
Rational peptide selection to detect human immunodeficiency virus type 1-specific T-cell responses under resource-limited conditionsC B Willberg, S K Pillai, E R Sharp, et al.
Scandinavian Journal of Immunology|January 16, 2004
Limited magnitude and breadth in the HLA-A2-restricted CD8 T-Cell response to Nef in children with vertically acquired HIV-1 infectionR Chandwani, K A Jordan, B L Shacklett, et al.
Pageof 6